This review is to describe synergistic effects of various combinations of dietary natural products including curcumin, quercetin, soybean isoflavones, silibinin, and EGCG that have potential for the treatment of prostate cancer. These data can provide valuable insights into the future rational design and development of synergistic and/or hybrid agents for potential treatment of prostate cancer.
Introduction
Dietary habit has been identified as one of the risk factors for prostate cancer as evidenced by several epidemiological studies. For example, Asian traditional food has been demonstrated to be correlated with the low incidence of prostate cancer in Asian men in contrast to soaring risk of prostate cancer in the Asian immigrants who live in the United States [1] . A variety of dietary agents (e.g. curcumin, quercetin, and silibinin) with diverse chemical structures ( Figure 1 ) have been verified by in vitro cell-based and in vivo animal studies to possess the potential for preventing and treating prostate cancer [2] [3] . The safety profiles enable these dietary natural products to be qualified as drug candidates. However, their moderate potency and poor bioavailability impede them in becoming effective chemotherapeutics when taken alone [4] [5] . Combination therapy might be an important strategy to overcome this problem in order to achieve enhanced overall clinical efficacy with acceptable clinical toxicity. Indeed, synergistic inhibition of growth, proliferation, and apoptosis of prostate cancer cells has been evident when using combinations of one dietary natural product with another natural product or with well-established chemotherapeutics. This review summarizes the synergistic effects of dietary anti-prostate cancer agents including curcumin, quercetin, soybean isoflavones, silibinin, and (-)-epigallocatechin-3-gallate (EGCG, Figure 1 ). These data can provide valuable insights into future rational design and development of synergistic and/or hybrid agents for potential treatment of prostate cancer. 
Synergistic effects of curcumin as anti-prostate cancer agents
Curcumin (Figure 1) , derived from Curcuma longa (turmeric) that has long been used for food flavoring and Ayurvedic medicine, represents a dietary natural product possessing potential in preventing and treating prostate cancer [2] . As summarized below, several studies have established the synergistic effects of curcumin in combination with either other natural products or clinical used chemotherapeutics as anti-prostate cancer agents.
Synergistic effects of curcumin with isoflavones:
Genistein (4',5,7-trihydroxyisoflavone, Figure 1 ) and daidzein (4',7dihydroxyisoflavone, Figure 2 ) are two chief isoflavones that were exclusively obtained from soybeans. When they were used for the respective single agent treatment, soybean milk, genistein, and daidzein were capable of inhibiting prostate cancer cell growth in vitro and tumor xenograft growth in vivo [6] .
Combined ingestion of soy isoflavones and curcumin has been unveiled by Ide and co-workers to substantially downregulate serum prostate-specific antigen levels for men who received biopsies in one clinical study [7] . Further investigation by the same research group indicated that the combination treatment of isoflavones and curcumin led to additive suppression of cell proliferation through activation of DNA damage response in LNCaP prostate cancer cells [8] . The synergism was also observed recently between curcumin and genistein in growth suppression of androgen-insensitive human prostate cancer cells [9] . Additionally, combined administration of curcumin and genistein exhibited more noticeable of the capability to inhibit cell proliferation and to induce apoptosis in androgeninsensitive PC-3 human prostate cancer cells than the respective single-agent treatment [10] .
Synergistic effects of curcumin with TRAIL:
TRAIL, also designated as Apo2L, is a cytokine member of the tumor necrosis factor family and plays as an extracellular signal that activates apoptosis in a variety of cancer cell lines, but exhibits little toxicity to normal cells [13] . In combination with its in vivo antitumor efficacy towards human tumor xenografts in nude mice, TRAIL is regarded as an appealing cytokine for the treatment of advanced cancers, such as advanced, metastatic prostate cancer [14] . However, TRAIL alone is not efficient enough for the treatment due to its drug resistance and moderate potency. The combination of TRAIL and dietary natural products with safety profiles might provide an alternative to chemotoxic agents to treat prostate cancer.
Curcumin has been shown in both in vitro and in vivo studies to sensitize both androgen-sensitive (LNCaP) and androgeninsensitive (PC-3) human prostate cancer cells to TRAIL-induced apoptosis [15] [16] . This sensitization was demonstrated by a followup study to be associated with downregulation of Akt-regulated nuclear factor-B (NF-B) and NF-B dependent anti-apoptotic proteins, including Bcl-2, Bcl-xL, and XIAP [17] . The in-depth in vivo animal experiment verified that curcumin and TRAIL combination appreciably reduced the growth of PC-3 prostate tumor xenografts in Balb/c nude mice by reducing the tumor growth rate to 139% and 147% for TRAIL-treated and curcumin-treated group, respectively, to 59% for the combined treatment group [16] .
Synergistic effects of curcumin with adenoviral mutants:
Adenoviruses have been identified as oncolytic virotherapeutic agents that can selectively replicate in and destroy cancer cells, but causing no harm to normal cells. Numerous viral mutants have been established as potential anti-prostate cancer agents, featuring clinical safety profiles. However, the clinical efficacy when administered alone needs to be improved due to its moderate potency. Combination administration of curcumin and tumor selective adenoviral mutant (Ad5) can amplify the cytotoxicity three to eight times towards both virus-sensitive 22R1 and virusinsensitive PC-3 human prostate cancer lines. This suggests that curcumin and Ad5 served as a potential combination of chemotherapy and oncolytic virotherapy [18] .
Synergistic effects of curcumin with bicalutamide:
Treatment of androgen-sensitive LNCaP prostate cancer cells with bicalutamide ( Figure 2 ), a nonsteroidal androgen receptor antagonist, at 10 µM for 24 hours resulted in notable suppression of cell proliferation. Significant antiproliferative effects of bicalutamide towards androgen-insensitive human prostate cancer cell lines (PC-3 and DU145) can only be observed at higher concentration and prolonged exposure time (30 µM, 72 hours). Intriguingly, a profound synergy has been observed between curcumin at low doses (10-20 µM) and bicalutamide in both androgen-sensitive and androgen-insensitive prostate cancer cell lines [19] . The potential underlying mechanism was correlated with phosphorylation escalation of extracellular signal-regulated kinase 1/2 (ERK1/2) and stress-activated protein kinase (SAPK)/Jun amino-terminal kinase (JNK).
Synergistic effects of curcumin with paclitaxel:
Curcumin has been demonstrated in vitro to considerably potentiate the cytotoxicity of paclitaxel ( Figure 2 ), a naturally occurring microtubule stabilizer and well-known clinically used anticancer drug, towards two androgen-insensitive DU145 and PC-3 human prostate cancer cell lines [20] . Intriguingly, this synergy can be affected by the treatment schedule. Sequential treatment with curcumin followed by paclitaxel yielded more significant synergism than concurrent treatment with curcumin/paclitaxel and sequential treatment with paclitaxel followed by curcumin [21] . The synergism between curcumin and paclitaxel in PC-3 prostate cancer cells was evidenced to be correlated with upregulation of p21WAF1/CIPI expression and downregulation of paclitaxel-induced nuclear factor kappa B.
Synergistic effects of curcumin with radiotherapy:
The limitation of radiotherapy, a frequent therapy for prostate cancer, is radio resistance. Radiotherapy failure has been more often observed in the prostate cancer patients with abnormal p53. Sensitization of curcumin on radiotherapy has been examined in one study [22] . It was concluded that the combination of curcumin and radiation can synergistically reduce cell viability and proliferation relative to either curcumin or radiation alone in both wild type p53-containing LNCaP and mutant p53-containing PC-3 human prostate cancer cell lines. Additionally, a synergistic effect independent of p53 status was also observed between curcumin and radiation towards clonogenic cell death in both LNCaP and PC-3 human prostate cancer cell lines.
Synergistic effects of quercetin as anti-prostate cancer agents
Quercetin, 3,3',4',5,7-pentahydroxyflavone ( Figure 1 ), is an ubiquitous flavonol widely occurring in a variety of edible vegetables and fruits. Several in vitro cell based evaluations indicate that quercetin processes cytotoxic and antiproliferative effects against a panel of prostate cancer cell lines, but not obvious toxicity towards normal prostate epithelial cells [3a] . The in vivo antiprostate tumor efficacy of quercetin has also been attested to by several animal experiments [23] . Combination treatment of quercetin with either other natural products or well-known chemotherapeutics was believed to be one good strategy to overcome its moderate potency and poor bioavailability. 
Synergistic effects of quercetin with genistein:
One clinical trial (ClinicalTrials.gov Identifier: NCT01538316) is investigating the effectiveness of the combination of genistein and quercetin in reducing the level of prostate-specific antigen (PSA) in patients with rising PSA. . The findings of this study showed (i) the two-flavonoid combinations at 25 µM (12.5 µM of each flavonoid) only exhibited additive effects in inhibiting prostate cancer cell proliferation; and (ii) the three-flavonoid combination (8.33 µM of quercetin, genistein, and biochanin A, respectively) can synergistically repress cell proliferation in three prostate cancer cell lines [24] . The androgen-insensitive PC-3 and DU145 human prostate cancer cell lines are more responsive to the combination treatments than the androgen-sensitive LNCaP cell line. Both two-flavonoid and threeflavonoid combinations can cause synergistic apoptosis and cell cycle arrest at the G 1 phase of PC-3 prostate cancer cells as evidenced by flow cytometric analysis [24] . Further investigation of the molecular mechanism revealed that the synergistic effects in PC-3 cells are associated with (i) the downregulation of c-myc, PCNA, mitogen activated protein kinase (MAPK)/ERK-1/2 signaling, and PI3K/AKT signaling pathway, and (ii) upregulation of ER- gene and MAPK/c-Jun N-terminal kinase signaling. The synergistic inhibition of cell-cycle in PC-3 cells is correlated with gene expression downregulation of cyclins D1 and E. The synergistic apoptosis contributed by the flavonoid combinations is related to the cooperative upregulation of caspase-3 and proapoptotic protein Bax, and to the collaborative downregulation of anti-apoptotic protein Bcl-2 in PC-3 cells [24] .
Synergistic effects of quercetin with genistein and biochanin

Synergistic effects of quercetin with green tea catechins:
The combination of quercetin with epigallocatechin gallate (EGCG, Figure 1 ) only exerts additive instead of synergistic effects in controlling proliferation of CWR22R1 and PC-3 prostate cancer cells [25] [26] . Intriguingly, a three-flavonoid combination consisting of quercetin, EGCG, and genistein can synergistically inhibit the CWR22R1 prostate cancer cell proliferation [25] . In contrast, androgen-sensitive LNCaP prostate cancer cells are more responsive to the treatment of quercetin combined with EGCG. The combination treatment acts synergistically in inhibiting proliferation, apoptosis, and cell cycle regulation of LNCaP cells [26] . Combination treatment of PC-3 and LNCaP prostate cancer cells with quercetin plus EGCG led to synergistically increased cellular absorption and decreased methylation of both EGCG and quercetin [26] . Additionally, the combination of quercetin and EGCG synergistically suppresses the self-renewal activities of prostate cancer stem cells, activates apoptosis, and prevents cancer stem cells' migration and invasion [27] .
The in vivo antitumor efficacy of green tea catechins has been shown to be improved by quercetin. A Phase I clinical study (ClinicalTrials.gov Identifier: NCT01912820) is designated to translate these preclinical results into a clinical setting by assessing the possible bioavailability improvement of quercetin and green tea catechins in combination.
Synergistic effects of quercetin with kaempferol:
The only structural difference between kaempferol (3,4',5,7tetrahydroxyflavone, Figure 3 ) and quercetin is that kaempferol lacks the 3'-OH group in quercetin. Kaempferol has been revealed to have antiproliferative effects towards prostate cancer cells with IC 50 values ranging from 10 to 55 µM [28]. Quercetin and kaempferol have been demonstrated to inhibit synergistically proliferation of androgen-sensitive LNCaP and androgeninsensitive PC-3 human prostate cancer cells [29]. (Figure 3 ) is a naturally occurring flavonoid belonging to the flavanone subclass, which only exhibits weak antiproliferative effects towards prostate cancer cells [29b]. Its synergistic effect on cell proliferation suppression towards the androgen-sensitive LNCaP prostate cancer cell line has been identified [29a] .
Synergistic effects of quercetin with naringenin: Naringenin
Synergistic effects of quercetin with arctigenin:
As mentioned in section 2.3, arctigenin is a naturally occurring lignan with promising antiproliferative activity towards prostate cancer cells. Arctigenin has been demonstrated to exhibit 10-to 20-fold stronger antiproliferative potency than quercetin in both LAPC-4 and LNCaP prostate cancer cell lines. LNCaP cells were more refractory to arctigenin than LAPC-4 cells. The treatment with arctigenin in combination with quercetin synergistically inhibits the cell proliferation in both prostate cancer cell lines. Cell proliferation suppression was enhanced by 30% in both cell lines by a combination treatment with arctigenin (1 µM) and quercetin (20 µM) as compared with the treatments with the individual compounds. The combination index values were in a range of 0.5-0.7 for LAPC-4 cells, and 0.2-0.8 for LNCaP cells [30] . The combination of quercetin plus arctigenin also led to the synergistic phosphorylation inhibition of multiple signaling molecules in LAPC-4 prostate cancer cells as determined by the intracellular signaling array analysis, as well as by Western blot analysis [30] . The synergistic downregulation of androgen receptor and prostate specific antigen in LAPC-4 cells was generated by the combination treatment as examined by qRT-PRC analysis and Western blot analysis. Additionally, the synergistic migration suppression of LAPC-4 and LNCaP prostate cancer cells was noticeably enhanced by the combination treatment [30] . (Figure 3 ), a specific antagonist of the estrogen receptor, has been demonstrated to be capable of potentiating the cytotoxic effect of chemotherapeutic agents in prostate cancer cell lines [31] . The in vivo synergistic efficacy of combined tamoxifen (10 mg/kg/week) plus quercetin (200 mg/kg/day) has been examined in CWR22 prostate tumor xenografts in severe combined immune deficient (SCID) mice. The results showed that combined tamoxifen with quercetin appreciably prolonged the appearance time of tumors by four days, reduced the final tumor volume by 73%, and lowered the tumor weight at the endpoint by 67%. As compared with the 2182 Natural Product Communications Vol. 10 (12) 2015 Vue et al.
Synergistic effects of quercetin with tamoxifen: Tamoxifen
individual agent treatment, a statistically significant synergism between quercetin and tamoxifen was established. The synergistic antitumor efficacy is linked with the modulation of angiogenesis [32] . (Figure 3) , an endogenous metabolite of 17βestradiol, has been revealed to inhibit growth and activate apoptosis of both androgen-sensitive and androgen-insensitive human prostate cancer cells by arresting cell cycle regulation in the G2/M phase [33] . One clinical study identified that 2-methoxyestradiol has a good safety profile for humans, but poor bioavailability as a drug candidate [34] . Wang et al. examined the growth inhibitory effects of sixteen combinations of quercetin (5, 10, 20, 40 μM) and 2methoxyestradiol (0.5, 1, 3, 5 μM) towards androgen-sensitive LNCaP and androgen-insensitive PC-3 human prostate cancer cell lines. Combination index values were in a range of 0.36-2.18 for LNCaP cells, and 0.32-1.77 for PC-3 cells. The combination index values indicated that synergistic effects can only be achieved when combining lower doses of quercetin (5 and 10 µM) with higher doses of 2-methoxyestradiol (3 and 5 µM) for LNCaP cells, and mixing higher doses of quercetin (20 and 40 µM) with higher doses of 2-methoxyestradiol (3 and 5 µM) for PC-3 cells [35] . The combination treatment for 48 hours significantly enhanced the apoptosis induction through regulation of anti-apoptotic Bcl-2 and proapoptotic Bax as compared with two individual treatments [35] . Additionally, the synergistic cell cycle regulation in the G2/M phase was also observed by treating LNCaP and PC-3 cells with quercetin plus 2-methoxyestradiol.
Synergistic effects of quercetin with 2-methoxyestradiol: 2-Methoxyestradiol
Synergistic effects of quercetin with TRAIL:
Combination treatment of quercetin (100 µM) and the death ligand TRAIL (10-100 ng/mL) for 24 hours generated strong synergistic cytotoxicity and apoptosis induction in androgen-insensitive DU-145 and PC-3 human prostate cancer cell lines, as determined by Annexin V and PI staining assays. The PC-3 cell line was illustrated to be more sensitive to the synergy of quercetin with TRAIL than the DU145 cell line even though these two cell lines are both tumorigenic and independent of wild-type p53. This disparity was assumed to be caused by an inherent dissimilarity in TRAIL sensitivity [36] . Further Western blot analysis displayed that the quercetin-induced sensitization to TRAIL-mediated DU145 cell apoptosis is linked to the upregulation of caspases -3, -8, and -9 [36] [37] [38] . Downregulation of survivin (anti-apoptotic protein) gene expression in both DU145 and PC-3 cell lines in an ERK-MSK1 dependent pathway was suggested to be a vital molecular mechanism associated with the apoptosis synergism between quercetin and TRAIL. Upregulation of DR5 (decoy receptor 5) protein expression by quercetin through enhancing transcription and protein stability has also been demonstrated by Jung et al. to be associated with its potentiating effect on the apoptosis of prostate cancer cells induced by TRAIL [37] . However, Kim and Lee did not observe any alteration of DR5 in their study when treating prostate cancer cells with quercetin in combination with TRAIL [38] . The combination of quercetin plus TRAIL has been revealed to exhibit a stronger synergistic cytostatic effect than synergistic cytotoxicity. The overriding feature of the combination is that the synergistic apoptosis is triggered by a mixture of an apoptotic "sensitizer" (quercetin) and an apoptotic "inducer" (TRAIL) [36] .
Synergistic effects of soybean isoflavones as anti-prostate cancer agents
4.1 Synergistic effects of genistein with daidzein: As indicated previously, genistein and daidzein are two isoflavones exclusively isolated from soybeans [6] . The only structural difference between genistein ( Figure 1 ) and daidzein ( Figure 2) is that daidzein lacks the hydroxyl group at C-5 of genistein. Genistein has been elicited to be more potent than daidzein in suppressing cell growth and proliferation of various prostate cancer cells [39] . Interestingly, the combination of daidzein and genistein exhibited greater antiproliferative and apoptotic effects than the respective single agent treatment towards androgen-sensitive LNCaP and its derived C4-2B human prostate cancer cell lines [40] . It is especially worth noting that an apparent apoptosis induction in C4-2B prostate cancer cells can be caused by the combination of genistein (50 µM) and daidzein (25-50 µM), but not individual genistein or daidzein. The synergism between genistein and daidzein might be contributed by their shared molecular mechanism of actions through modulating cell cycle and angiogenesis related genes and by the multi-target mechanism underlying the anti-proliferative effect of genistein. 
Synergistic effects of soybean isoflavones with tea:
In one in vivo animal study carried out by Zhou and co-workers in 2003, it was concluded that prostate tumor progression and metastasis can be synergistically suppressed by soy isoflavones (with genistein as its major chemical component) and tea (both green and black tea) in androgen-sensitive LNCaP human prostate tumor xenografts in severe combined immune deficient (SCID) mice [41] . They observed that (i) treatment of mice with soy phytochemicals and black tea in combination led to a 1.46-times greater effect on tumorigenicity rate than their additive effect; and (ii) combination treatment of soy phytochemicals and tea (both black and green tea) synergistically suppressed tumor metastasis to lymph nodes with ratios of 2.13 and 1.87. The synergistic effects might be linked to effective reduction of both testosterone and DHT in serum. (Figure 4) is synonymous with black tea polyphenols, which are transformed from green tea catechins (flavan-3-ols) catalyzed by polyphenol oxidase during tea leaf fermentation [42] . Thearubigin alone (up to 25 µg) neither showed any apparent cell growth inhibition nor DNA distribution change of cell cycle modulation in an androgen-insensitive prostate cancer cell line. However, a combination of thearubigin and genistein (1:40) appreciably enhanced cell growth suppression and cell cycle arrest at the G2/M phase as compared with the genistein-treated group [43] . Additionally, exposure of PC-3 prostate cancer cells to a combination of 2.5 µg/mL of genistein and 0.0625 µg/mL of thearubigin resulted in cell growth suppression by 33%. No cell growth inhibition was observed from either thearubigin-treated (0.0625 µg/mL) or genistein-treated (2.5 µg/mL) groups. This result thus confirmed the synergism between thearubigin and genistein. The molecular mechanism underlying the synergism is still elusive. Sakamoto et al. pointed out that genistein, but not thearubigin, can directly regulate the cell cycle. However, thearubigin in conjugation with genistein can synergistically cause cell cycle arrest at the G2/M phase and therefore repress cell growth.
Synergistic effects of genistein with thearubigin: Thearubigin
Synergistic effect of dietary natural product for the treatment of prostate cancer Natural Product Communications Vol. 10 (12) 2015 2183 4.4 Synergistic effects of genistein with 1,25-dihydroxyvitamin D 3 : Vitamin D deficiency has been hypothesized to be one of the primary risks for prostate cancer [44] . This hypothesis was not only corroborated by the correlation between the low incidence of prostate cancer and the vitamin D-rich Asian diet, but also confirmed by the antiproliferative effect of 1,25-dihydroxyvitamin D 3 (the most bioactive metabolite of vitamin D, Figure 4 ) against androgen-sensitive LNCaP human prostate cancer cells [45] . The inhibition of 1,25-dihydroxyvitamin D 3 on prostate cancer cell proliferation is linked to the nuclear vitamin D receptor. The soy isoflavone genistein (0.1 to 1 µM) and 1,25-dihydroxyvitamin D 3 (0.1 to 0.5 nM) have been demonstrated by Cramer and co-workers to possess synergistic effects on suppressing the growth of primary human prostatic epithelial cells and androgen-sensitive LNCaP human prostate cancer cells through cell cycle arrest [46] . The further mechanism exploration from the same research group demonstrated that 1,25-dihydroxyvitamin D 3 and genistein can act jointly to enhance the stability and subsequently the protein level of vitamin D receptor; and to escalate the levels of cell cycle inhibitor p21 that is essential to the anti-proliferative effects of both genistein and 1,25-dihydroxyvitamin D 3 . Accordingly, modulation of nuclear vitamin D signaling was concluded as one mechanism for the synergism between genistein and 1,25-dihydroxyvitamin D 3 [47] .
Synergistic effects of genistein with -lapachone: -
Lapachone (Figure 4) is an abundant naturally occurring quinone and can be readily obtained from Tabebuia avellanedae, the lapacho tree native to South America. -Lapachone has been shown to be a distinct Topo I inhibitor that suppresses the relevant enzymatic activity through directly binding to Topo I. Additionally, lapachone has been revealed to be capable of suppressing cell growth and promoting cell apoptosis in both androgen-sensitive and insensitive human prostate cancer cells [48] . The androgeninsensitive PC-3 human prostate cancer cells have been shown to be significantly more responsive to the combined administration of genistein and -lapachone when compared with the respective single-agent treatment [49] . Additionally, genistein and -lapachone have been demonstrated to act synergistically to induce apoptosis in the PC-3 cell line.
Synergistic effects of genistein with sodium selenite:
The anti-prostate cancer potential of selenite has been established based on various in vitro cell-based assays, in vivo animal experiments, and human clinical studies [50] . In search of a combination of antiprostate cancer agents with different underlying mechanisms, Zhao et al. evaluated the synergistic effects of genistein and selenite. The data revealed that the combination of genistein and selenite can synergistically induce cell apoptosis, cause cell cycle arrest at the G 2 /M phase, and modulate relevant signaling pathways in both androgen-sensitive LNCaP (p53-positive) and insensitive PC-3 (p53-negative) human prostate cancer cells [50] . The synergism was assumed to be partly due to their distinct molecular mechanisms. For example, selenite was shown to activate cell apoptosis but was not involved in cell cycle modulation. In contrast, genistein can cause both apoptosis activation and cell cycle modulation at the G 2 /M phase, which was contributed in part by downregulation of AKT [50] .
Synergistic effects of GCP with docetaxel:
GCP, with the isoflavones genistein and daidzein as the main chemical components, stands for a genistein combined polysaccharide that is marketed as a nutritional supplement. GCP with an enhanced absorption rate of genistein in the small intestine is generated from soybean extract catalyzed by mycelia. Docetaxel (Figure 4) , working by mainly promoting the polymerization of tubulin to microtubules and microtubule stabilization, is the current FDAapproved gold standard, first-line treatment for castration-resistant prostate cancer. The limitation of docetaxel's clinical efficacy is that it can barely prolong a maximum 2-3 years of survival for a prostate cancer patient [51] . Even worse, approximately 30,000 US men die each year of castration-resistant prostate cancer due to the inevitable progression of resistance to first-line treatment with docetaxel [52] .
To explore the possible advantage of GCP in combination with docetaxel for the treatment of castration-resistant prostate cancer, the in vitro antiproliferative and apoptotic effects of the combination of GCP and docetaxel were examined by Burich et al. in one androgen-sensitive LNCaP prostate cancer cell line and three androgen-insensitive CWR22R1, PC-3, and LNCaP-R273H prostate cancer cell lines. The results showed that GCP can potentiate docetaxel in inhibiting cell proliferation and promoting cell apoptosis in the four prostate cancer cell lines [53] . However, the degree of synergism between GCP and docetaxel is dependent on the administration schedule. Much greater synergism was observed in the LNCaP cell model when docetaxel rather than GCP was administered first in the sequential treatment.
Synergistic effects of GCP with bicalutamide:
GCP could also synergistically enhance the in vitro antiproliferative effects of androgen receptor antagonist bicalutamide ( Figure 2 ) in androgendependent LNCaP and androgen-independent LNCaP-R273H prostate cancer cell lines [53] . The LNCaP-R273H model, established from its parental LNCaP cell line by constitutive expression of the p53 gain-of-function mutation R273H, may better represent patient prostate tumor cells after progression to androgen insensitive. Parental LNCaP prostate cancer cells have been demonstrated to be far more responsive than the variant LNCaP-R273H subline to individual treatment with either GCP or bicalutamide. Intriguingly, both prostate cancer cell lines were wellsensitized to the combination of GCP and bicalutamide.
Synergistic effects of silibinin as anti-prostate cancer agents
Silymarin is a commercially available herb preparation that is extracted from the seeds of Silybum marianum (L.) Gaertn. Seven flavonolignans compose the critical chemical components of silymarin, with silibinin (a 1:1 mixture of diastereomers silybin A and silybin B, Figure 1) as the most abundant one [54] . The medicinal values of silymarin and silibinin as chemotherapeutics to treat hepatotoxicity have been extensively explored, especially in Europe and Asia [55] . Since 1998, the anti-prostate cancer potential of silymarin and silibinin has been evidenced by several in vitro cell-based evaluations and in vivo animal studies [56] . Their liver protective function, antiproliferative effects, and antitumor efficacy suggest the potential of silymarin and silibinin for clinical use, along with currently established cancer therapies, to improve synergistically the efficacy while alleviating toxicity for prostate cancer patient treatment [57] . Silymarin has already been used by cancer patients to eliminate the hepatotoxicity caused by several chemotherapies [58] . The synergistic effects of silibinin and chemotherapeutic drugs on cell proliferation, cell cycle modulation, and apoptosis activation in various cancer cell lines have been reviewed by Raina and Agarwal [59] . As described in the following subsections, silymarin and silibinin have been reported to be synergized with well-established chemotherapeutic agents including cisplatin, carboplatin, doxorubicin, docetaxel, and mitoxantrone as anti-prostate cancer agents.
Synergistic effects of silibinin with cisplatin/carboplatin:
Cisplatin and carboplatin belong to two platinum complexes that act as cytotoxic chemotherapeutics with molecular mechanism 2184 Natural Product Communications Vol. 10 (12) 2015 Vue et al.
underlying cytotoxicity similar to that of alkylating agents. Cisplatin [cis-diamminedichloroplatinum(II)] is a well-known and commonly used cytotoxic chemotherapy drug that was introduced into clinical trials in 1972. Its capability to form DNA adducts mainly contributes to the cytotoxicity of cisplatin [60] . However, its clinical efficacy is largely compromised by its high toxicity [61] . Carboplatin is another cytotoxic platinum complex with its full name as cis-diammine[1,1-cyclobutane-dicarboxylato]platinum. Compared with cisplatin, carboplatin has a better safety profile but no considerable effect towards castration-resistant prostate cancer [62] . Silibinin has been reported to potentiate cisplatin and carboplatin in inhibiting cell proliferation and activating cell apoptosis in the androgen-insensitive DU145 human prostate cancer cells. The synergistic effects on apoptosis were further confirmed by the results that the cleaved levels of PARP and Caspases 3, 7, and 9 were also synergistically upregulated by the combination regimen. The combination of silibinin (50-100 µM) with either cisplatin (2 µg/mL) or carboplatin (20 µg/L) has also been reported to cause synergistic cell cycle arrest at the G 2 -M phase and downregulate the relevant proteins of Cdc2, cyclin B1, and Cdc25C. It is worth noting that exposure of DU145 cells to cisplatin, carboplatin, and silibinin alone resulted in cell cycle arrest at G 2 -M, S, and G 1 phases, respectively. Both immunocytochemical and Western immunoblotting analyses indicated that combination treatment with silibinin and platinum complex led to a noticeable increase in the levels of cytosolic cytochrome c [63] . (Figure 5 ) is a well-known chemotherapeutic for a variety of cancers targeting topoisomerase II; its clinical efficacy, however, is limited by its high systemic toxicity. The synergism between silibinin and doxorubicin has been examined against both androgeninsensitive DU145 and androgen-sensitive LNCaP human prostate cancer cell lines [64] . The results showed that treatment with silibinin (25-100 µM) and doxorubicin (15-25 nM) alone or in combination led to considerable cell growth suppression in a dosedependent manner in both prostate cancer cell lines. However, DU145 cells are much more sensitive to the synergistic effects of silibinin and doxorubicin than LNCaP cells. It was established that the combination treatment of silibinin (100 µM) and doxorubicin (25 nM) generated a profound synergistic effect on inhibition of DU145 cell growth with combination index values in a range of 0.23-0.59. In contrast, almost no synergistic effect of silibinin (25 µM) and doxorubicin (15 nM) was observed on suppression of LNCaP cell growth with a combination index of 0.929. The perceived synergistic effects on growth suppression of DU145 cells were linked to intense cell cycle perturbation at the G 2 -M phase. The combination treatment caused up to 88% cell arrest in the G 2 -M phase while silibinin treatment alone caused G 1 arrest, and doxorubicin alone only caused moderate G 2 -M arrest (41%). Mechanistically, the combination of silibinin and doxorubicin can synergistically downregulate the G2-M cell cycle related protein expression, including cdc25C, cdc2/p34 and cyclin B1, and cdc2/p34 kinase activity affiliated with histone H1. Additionally, the combination treatment can also act synergistically in promoting DU145 cell apoptosis [65] . (Figure 4) is a well-established anticancer drug and inhibits cell division mainly through binding to and stabilizing microtubules. Docetaxel represents the first cytotoxic chemotherapeutic that offers survival benefit for patients with castration-resistant prostate cancer. For this reason, the US Food and Drug Administration (FDA) approved docetaxel in combination with predisone in 2004 for the first-line treatment in patients with castration-resistant prostate cancer [66] . However, an average 2.4 years of survival improvement and drug resistance make docetaxel less effective in the clinical use [67] . Chemotherapy with mitoxantrone ( Figure 5) , an inhibitor of topoisomerase II, has been shown to alleviate symptoms, but not prolong survival rate of patients with advanced castration-resistant prostate cancer [68] . In one study, only additive or even antagonistic effects on cell proliferation inhibition were observed when treating three human prostate cancer cell lines with silibinin in combination with docetaxel, with combination index values of 0.898-2.54 for DU145 cells, 0.921-2.32 for LNCaP cells, and 0.895-4.47 for PC-3 cells [69] . In contrast, the combination treatment of silibinin and mitoxantrone has been demonstrated to have noticeable synergy with combination index values in a range of 0.515-0.929 for DU145 cells, 0.521-0.967 for LNCaP cells, and 0.413-2.65 for PC-3 cells. The only exception is that antagonism was observed in the treatment of PC-3 cells with a low dose of mitoxantrone (e.g. 25 nM) in combined with silibinin [69] . To explore the molecular mechanism underlying the synergy between silibinin and mitoxantrone, the levels of caspase-3 and caspase-7 were evaluated. The results revealed that the combination treatment synergistically and significantly induced the apoptosis of three prostate cancer cell lines.
Synergistic effects of silibinin with doxorubicin: Doxorubicin
Synergistic effects of silibinin with docetaxel/mitoxantrone: Docetaxel
Synergistic effects of green tea catechins as anti-prostate cancer agents
Green tea crude extracts have been designated as green tea catechins that consist of a group of naturally occurring flavan-3-ols, with (-)-epigallocatechin-3-gallate (EGCG) as the most abundant one. Green tea catechins and EGCG have been demonstrated by several in vitro cell-based assays and in vivo animal studies to have potential in preventing and treating prostate cancer [11] . Several studies as shown in the following subsections have suggested that either green tea catechins or EGCG might be even more effective as anti-prostate agents when they synergistically act with other natural or non-natural compounds. The synergistic apoptosis induced by combinations of EGCG with anti-cancer drugs in various cancer cells (including prostate cancer cells) has been systemically reviewed [70] . transformation of arachidonic acid to prostaglandins. Highly expressed in prostate cancer tissue, prostaglandins are believed to serve as an essential role in the cell proliferation of prostate cancer. COX-2 is an inductive isoform and has been revealed to affect the proliferation and apoptosis of prostate cancer cells [72] . Consequently, COX-2 inhibitors have been proposed to be useful for potential chemotherapy for prostate cancer. (+)-Catechin ( Figure  6 ) is the simplest flava-3-ol derived from green tea, which showed certain cell proliferation suppression at a high concentration (100 µM) toward LNCaP and DU145 (but not PC-3) prostate cancer cell lines. Zaslau and co-workers reported that catechin and NS398 (a selective COX-2 inhibitor, Figure 6 ) would act synergistically to inhibit prostate cancer cell proliferation [72a] . Adhami and coworkers also explored the combinatorial effect of (-)epigallocateocatechin-3-gallate (EGCG) and selective COX-2 inhibitors (NS-398 and celecoxib, Figure 6 ) in both in vitro human prostate cancer cell models and in vivo prostate cancer CWR22Rv1 xenografts in athymic nude mice [71] . The in vitro synergism between EGCG and NS-398 was established because the combination treatment enhanced cell growth suppression and apoptosis activation, which was also supported by increased expression of Bax, pro-caspase-6, and pro-caspase-9, and poly (ADP)ribose polymerase cleavage. Additionally, the suppression of proliferator activated receptor  and nuclear factor-B were also enhanced as compared with their additive effects. Combination administration of EGCG and celecoxib in in vivo tumor xenografts led to improved anti-tumor efficacy, and decreased PSA levels and insulin-like growth factor-1 levels.
Synergistic effects of EGCG with ibuprofen:
Ibuprofen ( Figure 6 ) is a well-established non-steroidal anti-inflammatory drug (NASID) that functions via inhibiting cyclooxygenase (COX) enzymes. Administration of ibuprofen was associated with low incidence of prostate cancer probably due to its ability to suppress COX enzymes [73] . The in vitro study has revealed that ibuprofen can inhibit cell proliferation and activate cell apoptosis in LNCaP prostate cancer cells [74] . The synergism between EGCG and ibuprofen has been established by in vitro cell-based assays, in which they can act synergistically in inhibiting cell proliferation and inducing cell apoptosis in both androgen-insensitive and sensitive (PC-3, DU145, and LNCaP) prostate cancer cell lines [75] . The further underlying mechanism investigation indicated that combined treatment of PC-3 cells can synergistically upregulate protein phosphatase 1 activity and subsequently activate alternative splicing of anti-apoptotic proteins Bcl-X and Mcl-1 [75b].
Synergistic effects of green tea catechins with black tea theaflavin:
As mentioned previously, EGCG represents the most copious flavan-3-ol in green tea while theaflavin ( Figure 6 ) is the major flavonoid polymer in black tea. Interestingly, EGCG and theaflavin can function synergistically to decrease the growth rate of prostate cancer as compared with either EGCG or theaflavin alone. This synergism may be caused by functionally supplemented mechanisms of EGCG and theaflavin [76] .
Synergistic effects of green tea catechins with luteolin:
It has been demonstrated that prostate cancer progression can be driven by the existence of myofibroblasts and that EGCG may suppress the myofibroblast differentiation relevant to prostate cancer [77] . Luteolin, 3',4',5,7-tetrahydroxyflavone ( Figure 6 ), is another ordinary flavone and can be readily obtained from a variety of vegetables and fruits, as well as traditional Chinese medicines [78] . Several in vitro and in vivo studies have shown its potential in preventing and treating prostate cancer [79] . Luteolin can potentiate EGCG to upregulate fibronectin expression in prostate fibroblast cell lines [77] . Consequently, myofibroblast phenotypes and extracellular matrix contraction (a promoter of cancer cell invasion) mediated by TGF- can be synergistically suppressed by combinations of EGCG and luteolin at micromolar concentrations. Mechanistically, EGCG and luteolin can individually downregulate ERK and Rho that are downstream signalings induced by TGF-and are essential for fibronectin expression [77] . Additionally, EGCG and luteolin have been shown to reverse synergistically fibronectin expression induced by TGF-. These findings suggested that the combination of EGCG and luteolin might be clinically useful in preventing and reversing prostate cancer progression via targeting the tumor microenvironment rather than the tumor itself.
Synergistic effects of EGCG with TRAIL:
TRAIL is known to inhibit cell proliferation in PC-3 instead of LNCaP prostate cancer cells. The synergism between EGCG and TRAIL has been identified according to the following experimental findings: (i) combination treatment of EGCG and TRAIL enhanced antiproliferative effects towards TRAIL refractory LNCaP cells as compared with the single-agent treatments; (ii) the combination treatment led to escalated apoptosis of LNCaP cells relative to effects caused by the single treatments; and (iii) the combination treatment resulted in a synergistic suppression of the invasion and migration of LNCaP cells [80] . The improved apoptosis contributed by the combined treatment is linked to both intrinsic and extrinsic pathways through several molecular mechanisms. For example, the apoptosis was found to be accompanied by the increased poly(ADPribose)polymerase cleavage and pro-apoptotic proteins, together with reduced anti-apoptotic proteins.
Synergistic effects of EGCG with taxanes:
The combination of ECGC and either paclitaxel ( Figure 2 ) or docetaxel ( Figure 4 ) generated synergistic efficacy in vitro and in vivo [81] . The in vitro cell-based studies have unveiled that EGCG (30 µM) in combination with either paclitaxel (6.25 nM) or docetaxel (3.12 nM) exhibited synergistic effects in inhibiting proliferation and activating apoptosis of PC-3ML human prostate cancer cells. The in vivo animal studies indicated that the synergistic effects in suppressing PC-3ML tumor xenograft growth were generated for the combined treatment with EGCG and docetaxel in severe combined immunodeficient mice. In addition to attenuating the preexisting PC-3ML tumor xenografts, the combined treatment increased disease-free survival rates to greater than 90%. EGCG combined with either paclitaxel or docetaxel through intraperitoneal injection (i.p.) promoted a considerable enhancement in apoptosis rates, as determined by TUNEL assays. The in vitro cell-based assays and in vivo mechanism studies in mice have also revealed that EGCG and either paclitaxel or docetaxel can act synergistically to upregulate certain apoptotic genes [81] .
Synergistic effects of EGCG with doxorubicin:
Doxorubicin is a well-known chemotherapeutic for a variety of cancers. Low doses of doxorubicin have been demonstrated by in vitro studies to act synergistically with EGCG in inhibiting cell proliferation and colony forming of PC-3ML human prostate cancer cells. The synergism between EGCG and doxorubicin was also verified by in vivo animal studies in mice implanted with advanced, metastatic PC-3ML human prostate cancer cells. The data showed that the combined treatment led to synergistic suppression of tumor xenograft growth, elimination of tumors, and enhancement of mouse survival rates [82] . Additionally, EGCG was also demonstrated to escalate doxorubicin retention by the prostate cancer cells in vitro and by the metastatic tumor xenografts in vivo.
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Synergistic effects of EGCG with cisplatin:
As described in section 5.1, cisplatin is a well-known and commonly used cytotoxic chemotherapy drug that processes promising efficacy but high toxicity. EGCG (25 µM) has been evidenced to induce synergistically apoptosis of PC-3 prostate cancer cells in combination with cisplatin (2.5 µM) as compared with the effects caused by treating the individual agent alone [83] . 6.9 Synergistic effects of EGCG with free Zn 2+ : Zinc is an essential trace element. The elevated level of intracellular zinc has been demonstrated to be linked with decreased proliferation and increased apoptosis of prostate cancer cells [84] . The antiproliferative activities of Zn 2+ /EGCG mixture and zinc-EGCG complex were examined on an androgen-insensitive PC-3 human prostate cancer cell line. It was revealed that free Zn 2+ can potentiate the antiproliferative effect of EGCG on PC-3 cells [85] .
Conclusion
These data can provide valuable insights into future design and development of multi-targeting and synergistic agents for potential treatment of prostate cancer. However, most currently available data are only derived from in vitro evaluations. The molecular mechanism of the underlying synergism is still elusive. The indepth mechanism investigation of the synergism of dietary natural products and the rational application of the synergism to the design of hybrid molecules would thus be a good future direction for the development of potential anti-prostate cancer agents.
